Clinical trial
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets…
NCT00268957 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00268957 |
|---|---|
| Title | Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis |
| Official title | A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease |
| Intervention type | Drug |
| Interventions | Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®) |
| Enrollment | 217 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 23, 2005 |
| Last update posted | Mar 19, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: